Meeting
2022 ASCO Annual Meeting
Nivolumab and lenvatanib combination for fibrolamellar carcinoma.
Authors
Paul Kent
Rush University Medical Center, Chicago, IL
Paul Kent , Erik Schadde , Oliver M Fisher , Albert Cornelius , Emma Estberg , Jessica Ellison , Thomas Kim , Jordan C Tasse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4111)
DOI
10.1200/JCO.2022.40.16_suppl.4111
Abstract #
4111
Poster Bd #
98
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Early experience with nivolumab, gemcitabine, and lenvatinib for fibrolamellar hepatocellular carcinoma.
First Author: Paul Kent
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
First Author: Ralph Zinner
Poster
2019 ASCO Annual Meeting
Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response.
First Author: Joshua E. Reuss
Poster
2019 Gastrointestinal Cancers Symposium
Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.
First Author: Sakti Chakrabarti